Veradermics MANE
NYSE MANE
$116.17 -1.05 (-0.90%)
As of: Oct 2, 2026 · 2:48 PM EDT

Veradermics (MANE) Cash & Equivalents (2024 - 2026)

Updated

Veradermics' Cash & Equivalents was $319.33 million in Q2 2026, up 89.6% from the prior quarter.

Analysis

Veradermics (MANE) Cash & Equivalents (2024 - 2026) Analysis & Trends

At the end of FY2025, Cash & Equivalents at Veradermics came in at $21.77 million, down 59.0% from FY2024.

  • In earlier years, Cash & Equivalents was $53.08 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 20.42 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 6.57 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.85 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 7.62 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 4.89 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 13.99 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 3.18 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 976.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 6.14 Bn
10 Veradermics 5.07 Bn 5.07 Bn - 319.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 319.33 Mn
Mar 31, 2026 168.41 Mn
Dec 31, 2025 21.77 Mn
Dec 31, 2024 53.08 Mn
API Access

Veradermics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=MANE&period=max&api_key=YOUR_API_KEY